164 related articles for article (PubMed ID: 22547083)
1. Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3.
Subramanian M; Agrawal V; Sandee D; Tam HK; Miller WL; Tracy TS
Pharmacogenet Genomics; 2012 Aug; 22(8):590-7. PubMed ID: 22547083
[TBL] [Abstract][Full Text] [Related]
2. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro.
Sandee D; Morrissey K; Agrawal V; Tam HK; Kramer MA; Tracy TS; Giacomini KM; Miller WL
Pharmacogenet Genomics; 2010 Nov; 20(11):677-86. PubMed ID: 20940534
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19.
Agrawal V; Huang N; Miller WL
Pharmacogenet Genomics; 2008 Jul; 18(7):569-76. PubMed ID: 18551037
[TBL] [Abstract][Full Text] [Related]
4. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase.
Agrawal V; Choi JH; Giacomini KM; Miller WL
Pharmacogenet Genomics; 2010 Oct; 20(10):611-8. PubMed ID: 20697309
[TBL] [Abstract][Full Text] [Related]
5. Consequences of POR mutations and polymorphisms.
Miller WL; Agrawal V; Sandee D; Tee MK; Huang N; Choi JH; Morrissey K; Giacomini KM
Mol Cell Endocrinol; 2011 Apr; 336(1-2):174-9. PubMed ID: 21070833
[TBL] [Abstract][Full Text] [Related]
6. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
Velazquez MNR; Parween S; Udhane SS; Pandey AV
Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
[TBL] [Abstract][Full Text] [Related]
7. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
Flück CE; Nicolo C; Pandey AV
Fundam Clin Pharmacol; 2007 Aug; 21(4):399-410. PubMed ID: 17635179
[TBL] [Abstract][Full Text] [Related]
8. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis.
Locuson CW; Wienkers LC; Jones JP; Tracy TS
Drug Metab Dispos; 2007 Jul; 35(7):1174-81. PubMed ID: 17446262
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 oxidoreductase variant A503V contributes to the increased CYP3A5 activity with tacrolimus
Gao Y; Ma J
Expert Opin Drug Metab Toxicol; 2022; 18(7-8):529-535. PubMed ID: 35946839
[TBL] [Abstract][Full Text] [Related]
11. P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms.
Burkhard FZ; Parween S; Udhane SS; Flück CE; Pandey AV
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):38-50. PubMed ID: 27068427
[TBL] [Abstract][Full Text] [Related]
12. Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.
Tomalik-Scharte D; Maiter D; Kirchheiner J; Ivison HE; Fuhr U; Arlt W
Eur J Endocrinol; 2010 Dec; 163(6):919-24. PubMed ID: 20844025
[TBL] [Abstract][Full Text] [Related]
13. Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6.
Chen X; Pan LQ; Naranmandura H; Zeng S; Chen SQ
PLoS One; 2012; 7(6):e38495. PubMed ID: 22719896
[TBL] [Abstract][Full Text] [Related]
14. The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency.
Gomes LG; Huang N; Agrawal V; Mendonça BB; Bachega TA; Miller WL
J Clin Endocrinol Metab; 2008 Jul; 93(7):2913-6. PubMed ID: 18397975
[TBL] [Abstract][Full Text] [Related]
15. P450 oxidoreductase deficiency: a disorder of steroidogenesis with multiple clinical manifestations.
Miller WL
Sci Signal; 2012 Oct; 5(247):pt11. PubMed ID: 23092891
[TBL] [Abstract][Full Text] [Related]
16. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.
Crespi CL; Miller VP
Pharmacogenetics; 1997 Jun; 7(3):203-10. PubMed ID: 9241660
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis.
Subramanian M; Low M; Locuson CW; Tracy TS
Drug Metab Dispos; 2009 Aug; 37(8):1682-9. PubMed ID: 19448135
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy.
Gong L; Zhang CM; Lv JF; Zhou HH; Fan L
Pharmacogenet Genomics; 2017 Sep; 27(9):337-346. PubMed ID: 28731962
[TBL] [Abstract][Full Text] [Related]
19. Impact on CYP19A1 activity by mutations in NADPH cytochrome P450 oxidoreductase.
Flück CE; Pandey AV
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):64-70. PubMed ID: 27032764
[TBL] [Abstract][Full Text] [Related]
20. Electron transfer by human wild-type and A287P mutant P450 oxidoreductase assessed by transient kinetics: functional basis of P450 oxidoreductase deficiency.
Jin Y; Chen M; Penning TM; Miller WL
Biochem J; 2015 May; 468(1):25-31. PubMed ID: 25728647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
